company background image
ROVI

Laboratorios Farmaceuticos Rovi BME:ROVI Stock Report

Last Price

€36.20

Market Cap

€1.9b

7D

-2.3%

1Y

-45.6%

Updated

08 Dec, 2022

Data

Company Financials +
ROVI fundamental analysis
Snowflake Score
Valuation6/6
Future Growth3/6
Past Performance6/6
Financial Health6/6
Dividends4/6

ROVI Stock Overview

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally.

Laboratorios Farmaceuticos Rovi, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Laboratorios Farmaceuticos Rovi
Historical stock prices
Current Share Price€36.20
52 Week High€74.90
52 Week Low€35.68
Beta0.45
1 Month Change-5.24%
3 Month Change-22.48%
1 Year Change-45.56%
3 Year Change45.97%
5 Year Change117.42%
Change since IPO262.00%

Recent News & Updates

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Recent updates

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Jun 15
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Feb 13
I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Jan 02
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Dec 12
A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Nov 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Sep 24
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Jun 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Apr 06
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

Mar 15
Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Feb 16
If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

Jan 26
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Dec 14
Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

Nov 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 06
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate

Shareholder Returns

ROVIES PharmaceuticalsES Market
7D-2.3%-0.4%-2.2%
1Y-45.6%0.5%-3.6%

Return vs Industry: ROVI underperformed the Spanish Pharmaceuticals industry which returned 0.9% over the past year.

Return vs Market: ROVI underperformed the Spanish Market which returned -3.5% over the past year.

Price Volatility

Is ROVI's price volatile compared to industry and market?
ROVI volatility
ROVI Average Weekly Movement6.3%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement4.1%
10% most volatile stocks in ES Market6.5%
10% least volatile stocks in ES Market0.6%

Stable Share Price: ROVI is more volatile than 75% of Spanish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ROVI's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Spanish stocks.

About the Company

FoundedEmployeesCEOWebsite
19461,852Juan Lopez-Belmonte Encinahttps://www.rovi.es

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers.

Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary

How do Laboratorios Farmaceuticos Rovi's earnings and revenue compare to its market cap?
ROVI fundamental statistics
Market Cap€1.93b
Earnings (TTM)€175.64m
Revenue (TTM)€760.67m

11.0x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ROVI income statement (TTM)
Revenue€760.67m
Cost of Revenue€303.51m
Gross Profit€457.17m
Other Expenses€281.52m
Earnings€175.64m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)3.29
Gross Margin60.10%
Net Profit Margin23.09%
Debt/Equity Ratio12.4%

How did ROVI perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

29%

Payout Ratio